Dermata stock is trading at elevated levels. What’s ahead for DRMA stock?USPTO Issues Notice Of AllowanceThe U.S. Patent and Trademark Office issued Dermata Therapeutics a notice of allowance for a U.S. patent titled "Compositions for the Treatment of Skin Conditions," signaling that the application has met the necessary requirements and is expected to be granted following standard administrative procedures.Technical Indicators Suggest Early Rebound, Momentum Still WeakDRMA is trading 18.2% above its 20-day ...